精神分裂症患者心肌梗死后二级预防心血管治疗与死亡率的关联
这项丹麦全国性队列研究纳入1995至2015年首次心肌梗死的105 018例患者,其中684例精神分裂症患者。结果显示未接受心脏保护药物的精神分裂症患者死亡率最高(HR 8.78),接受三联治疗者死亡率与一般人群相近(HR 1.05)。提示有效管理二级预防治疗可改善精神分裂症患者心梗后预后。
要点
- 精神分裂症患者心梗后未接受心脏保护药物者死亡率显著高于一般人群治疗者(HR 8.78)。
- 接受任何三联治疗组合的精神分裂症患者死亡率与一般人群相近(HR 1.05)。
- 心梗后应仔细管理精神分裂症患者的心脏保护药物以改善预后。
核心结论
- 心肌梗死后应仔细管理心脏保护药物以改善精神分裂症患者预后。
- 有效给予二级预防治疗组合可能降低精神分裂症患者部分增高的心脏死亡率。
研究设计与样本
- 队列按是否诊断精神分裂症二分,共105 018例,其中精神分裂症684例(0.7%),一般人群104 334例(99.3%)。
- 暴露为心脏保护药物(抗血栓药、β受体阻滞剂、维生素K拮抗剂、ACE抑制剂、他汀类)处方时间。
- 采用Cox比例风险回归计算治疗暴露与心梗后全因死亡关联的HR及95%CI。
主要发现
- 总随访796 435人年,共28 059例死亡。
- 未接受心脏保护药物治疗的精神分裂症患者死亡率最高(HR 8.78;95%CI 4.37-17.64),对照为接受治疗的一般人群。
- 接受治疗的精神分裂症患者HR为1.97(95%CI 1.25-3.10)。
- 接受任何三联治疗组合的精神分裂症患者死亡率与一般人群相近(多变量分析HR 1.05;95%CI 0.43-2.52)。
关键数值与推荐
- 精神分裂症患者684例中男性483例(70.6%),诊断时平均年龄57.3(SD 10.6)岁。
- 一般人群患者104 334例中男性73 454例(70.4%),诊断时平均年龄61.0(SD 10.6)岁。
临床怎么用
- 对心肌梗死后的精神分裂症患者应仔细管理指南推荐的心脏保护药物。
- 给予二级预防治疗组合可能降低精神分裂症患者心梗后增高的死亡风险。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: Cardioprotective medication use is an important secondary preventive treatment after cardiovascular events. Patients with schizophrenia have excess cardiovascular morbidity and mortality, but no studies have investigated whether taking recommended cardioprotective medication can reduce this excess mortality. OBJECTIVE: To assess the association of exposure to secondary cardiovascular treatment with all-cause mortality after myocardial infarction among patients with schizophrenia compared with the general population. DESIGN, SETTING, AND PARTICIPANTS: This nationwide cohort study included individuals admitted with first-time myocardial infarction in Denmark from January 1, 1995, to December 31, 2015. The cohort was dichotomously divided by a diagnosis of schizophrenia. Data on the prescription of guideline-recommended cardioprotective medication, including antithrombotics, β-blockers, vitamin K antagonist, angiotensin-converting enzyme inhibitors, and statins, were obtained from the nationwide registries. EXPOSURES: Time exposed to cardioprotective medication. MAIN OUTCOMES AND MEASURE: Cox proportional hazards regression was used to calculate hazard ratios (HRs) with 95% CIs for the association between treatment exposure and all-cause mortality after myocardial infarction between patients with and without schizophrenia. RESULTS: The cohort included 105 018 patients with myocardial infarction, including 684 patients with schizophrenia (0.7%; 483 male [70.6%]; mean [SD] age at diagnosis, 57.3 [10.6] years) and 104 334 general population patients (99.3%; 73 454 male [70.4%]; mean [SD] age at diagnosis, 61.0 [10.6] years), with a total follow-up of 796 435 person-years and 28 059 deaths. Patients diagnosed with schizophrenia who did not receive cardioprotective treatment had the highest mortality rate (HR, 8.78; 95% CI, 4.37-17.64) compared with the general population treated, with treated patients diagnosed with schizophrenia having an increased HR of 1.97 (95% CI, 1.25-3.10). The analyses of the associations of different cardiac therapy strategies with mortality rates revealed that patients with schizophrenia who were treated with any combination of triple therapy had mortality rates similar to those observed in the general population (HR, 1.05; 95% CI, 0.43-2.52) in the multivariable analysis. CONCLUSIONS AND RELEVANCE: Cardioprotective medication after myocardial infarction should be carefully managed to improve prognosis. The study results suggest that some of the increased cardiac mortality among patients with schizophrenia can be reduced if these patients are efficiently administered combinations of secondary preventive treatments after cardiac events.
引用
- Kugathasan P, Horsdal HT, Aagaard J, et al. Association of Secondary Preventive Cardiovascular Treatment After Myocardial Infarction With Mortality Among Patients With Schizophrenia. JAMA Psychiatry. 2018. PMID: 30422158. doi:10.1001/jamapsychiatry.2018.2742
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。